Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Net income | -$28.6M | -$66.4M | -$107M | -$157M | -$211M | -$259M | -$414M | -$506M |
| EPS (diluted) | -$1.29 | -$1.54 | -$1.22 | -$1.43 | -$1.71 | -$1.88 | -$2.73 | -$2.77 |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$28.5M | -$53.4M | -$83.3M | -$106M | -$188M | -$214M | -$376M | -$407M |
| Capital expenditures | $52.0K | $31.0K | $210K | $254K | $197K | $360K | $759K | $8.00K |
| Free cash flow | -$28.6M | -$53.4M | -$83.5M | -$106M | -$188M | -$215M | -$377M | -$407M |
| Fiscal year | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $6.99M | $101M | $400M | $494M | $377M | $635M | $714M | $902M |
| Total assets | $13.8M | $109M | $412M | $516M | $406M | $666M | $776M | $957M |
| Total liabilities | $6.49M | $15.3M | $21.0M | $45.7M | $43.3M | $48.6M | $68.8M | $104M |
| Shareholders' equity | $7.34M | $94.1M | $391M | $470M | $362M | $618M | $707M | $853M |
| Retained earnings | -$24.8M | -$91.2M | -$199M | -$355M | -$566M | -$826M | -$1.24B | -$1.75B |
| Shares (wtd avg diluted) | 38.6M | 54.7M | 87.8M | 110M | 123M | 138M | 152M | 182M |
Every figure is extracted from Immunovant, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.